Founders Club member German cleantech company LaTherm announces significant customer deployment with Bottrop InnovationCity

http://www.youtube.com/watch?v=GEtB8e0yMjo

Zurich, Switzerland, November 29, 2010

Covagen, an ETH Zurich spin-off company pioneering the development of a novel class of protein therapeutics (Fynomers), announced today the closing of a Series A financing round in which CHF 6.3 million was raised.

ST. PAUL, MN — November 8, 2010 —

Ernst & Young LLP has named John Romans, President and CEO of BioMedix Vascular Solutions, Inc. an Ernst & Young Entrepreneur Of The Year for the Technology category in the Upper Midwest Region. Mr. Romans was selected as a winner by an independent judging panel made up of regional business, academic and community leaders.

Zurich-Schlieren, Switzerland, November 8th 2010 - Covagen (CH) announced today that the collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY), which began in 2009, has been extended. Under the new agreement, Covagen will use its proprietary technology to isolate Fynomers binding to targets provided by Roche. Fynomers delivered by Covagen will be used by Roche as a research tool to discover new treatment modalities. The financial terms of this agreement were not disclosed.

Dr. Julian Bertschinger, CEO and co-founder of Covagen commented: “After the successful completion of all milestones of the previous contract we are proud to extend the [ … ]

Freising-Weihenstephan, Germany, September 28, 2010 -- Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), under which Pieris will apply its proprietary Anticalin technology to discover novel Anticalin drugs against multiple targets, with further development undertaken by Sanofi-Aventis and Sanofi-Pasteur. The collaboration will initially involve two targets nominated by Sanofi-Aventis and Sanofi-Pasteur, and includes the option for four additional targets.